FDA Accepts Dapagliflozin Application from Centaur Pharmaceuticals
The FDA has accepted the application ANDA220679 for dapagliflozin from Centaur Pharmaceuticals.
Asset / Drug
Drug and asset intelligence for Dapagliflozin with 20 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
SGLT2 Inhibitor
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.